EDIT
NASDAQ · Biotechnology
Editas Medicine Inc
$2.51
-0.07 (-2.71%)
Open$2.55
Previous Close$2.58
Day High$2.55
Day Low$2.42
52W High$4.54
52W Low$1.66
Volume—
Avg Volume4.14M
Market Cap395.47M
P/E Ratio—
EPS$-0.74
SectorBiotechnology
Analyst Ratings
Buy
18 analysts
Price Target
+410.4% upside
Current
$2.51
$2.51
Target
$12.81
$12.81
$8.62
$12.81 avg
$14.59
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 67.13M | 52.79M | 30.54M |
| Net Income | -265,155,080 | -187,683,501 | 4.38M |
| Profit Margin | -395.0% | -375.3% | 14.4% |
| EBITDA | -256,334,219 | -191,519,864 | 9.59M |
| Free Cash Flow | — | — | 5.15M |
| Rev Growth | +27.2% | +27.2% | +16.6% |
| Debt/Equity | 2.15 | 2.15 | 0.64 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |